ECOG, Cancer and Leukemia Group B (Alliance), SWOG, and
Mayo Clinic
No affiliation available
Citations 1
CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rec
Lenz, Heinz‐Josef , Innocenti, Federico , Mahoney, Michelle R., O’Neil, Bert H. , Polite, Blasé N. , Höchster, Howard S. , Atkins, James N., Goldberg, Richard M. , Schilsky, Richard L. , Blanke, Charles D. , ECOG, Cancer and Leukemia Group B (Alliance), SWOG, and, Venook, Alan P. , Niedzwiecki, Donna , Shaw, James Edward , Mayer, Robert J. , Bertagnolli, Monica M. , ECOG, Cancer and Leukemia Group B (Alliance), SWOG, and
Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: LBA3-LBA3
